Risperidone , ≥98% , 106266-06-2

Synonym(s):
R 64,766;Risperidone

CAS NO.：106266-06-2

Empirical Formula: C23H27FN4O2

Molecular Weight: 410.48

MDL number: MFCD00274576

EINECS: 600-733-1

PRODUCT Properties

• Melting point: 170°C
• Boiling point: 572.4±60.0 °C(Predicted)
• Density: 1.38±0.1 g/cm3(Predicted)
• Flash point: 9℃
• storage temp.: 2-8°C
• solubility: DMSO: ≥5mg/mL
• pka: pKa 8.3 (Uncertain)
• form: powder
• color: white to off-white
• Water Solubility: 44.74mg/L(25 ºC)
• Merck: 14,8233
• BCS Class: 2
• CAS DataBase Reference: 106266-06-2(CAS DataBase Reference)

Description and Uses

Risperidone is a novel antipsychotic introduced for the treatment of acute and chronic schizophrenia. It has a balanced serotonin 5-HT₂ and dopamine D₂ receptor antagonist activity. While the anti-D₂ activity may relate to the antipsychotic potency of neuroleptic agents, an antidepressive efficacy of substances with anti-5-HT₂ activity has been suggested. Risperidone, therefore, has therapeutic action on both positive and negative symptoms of schizophrenia and produces significantly fewer side effects especially extrapyramidal symptoms compared with commonly used pure D₂ antagonist antipsychotics. It also has potential for management of alcohol withdrawal and cocaine addiction.

For the treatment of schizophrenia in adults and in adolescents, ages 13 to 17, and for the short-term treatment of manic or mixed episodes of bipolar I disorder in children and adolescents ages 10 to 17. May also be used to manage symptoms of inappropria

Safety

• Symbol(GHS): GHS06
• Signal word: Danger
• Hazard statements: H301
• Precautionary statements: P301+P310
• Hazard Codes: T,F
• Risk Statements: 25-39/23/24/25-23/24/25-11
• Safety Statements: 28-36-45-36/37-16
• RIDADR: 3249
• WGK Germany: 3
• RTECS: UV1164800
• HazardClass: 6.1(a)
• PackingGroup: II
• HS Code: 29333990
• Hazardous Substances Data: 106266-06-2(Hazardous Substances Data)
• Toxicity: LD50 in male, female mice, rats, dogs (mg/kg): 29.7, 26.9, 34.3, 35.4, 14.1, 18.3 i.v.; 82.1, 63.1, 113, 56.6, 18.3, 18.3 orally (Janssen, 1988)